Summary
The extracted claims regarding U.S. brand names cannot be verified against FDA-approved prescribing information because no label text or relevant label sections were provided.
Category Scores
Accurate Statements
Unsupported Statements
In the U.S., pramipexole immediate-release is commonly sold under the brand name Mirapex.
Not supported/verifyable against the supplied FDA labeling material (no label sections/excerpts provided). Marked absent_from_the_label in the provided evaluation context due to missing label text rather than confirmation of absence.
In the U.S., pramipexole extended-release is commonly marketed under the brand name Mirapex ER.
Not supported/verifyable against the supplied FDA labeling material (no label sections/excerpts provided). Marked absent_from_the_label in the provided evaluation context rather than confirmation of absence.
Contradictions
Important Omissions
FDA-approved prescribing information excerpts/sections for pramipexole immediate-release and extended-release sufficient to verify brand/product naming.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated are about brand-name marketing/sales rather than safety, dosing, contraindications, or required administration/storage instructions. However, label adherence could not be confirmed due to missing label content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Verifiable
Primary Issue
No FDA label text/sections were provided to verify the brand-name assertions (Mirapex vs Mirapex ER).
Suggested Improvement
Provide the FDA-approved label excerpts (with section references) for pramipexole immediate-release and extended-release—particularly any product naming/brand identification and 'How Supplied/Storage and Handling'—so brand-name claims can be checked.